THE USE OF ANTIBODIES IN TREATING HIV INFECTION AND SUPPRESSING HIV TRANSMISSION
In one aspect, the disclosure provides methods of treating HIV and decreasing the chance of HIV infection in a subject, and compositions used in these methods.
1 . A method of treating HIV infection in a subject, the method comprising administering to the subject: a composition comprising IgA antibody; a composition comprising multimeric antibody; or a composition comprising highly glycosylated antibody, to treat HIV infection.
2 .- 5 . (canceled)
6 . The method of claim 1 , wherein the IgA antibody is produced in the mammary gland of a transgenic non-human mammal.
7 . (canceled)
8 . A method of decreasing the chance of HIV infection in a subject, the method comprising administering to the subject: a composition comprising IgA antibody; a composition comprising multimeric antibody; or a composition comprising highly glycosylated antibody, to decrease the chance of HIV infection.
9 .- 12 . (canceled)
13 . The method of claim 8 , wherein the IgA antibody is produced in the mammary gland of a transgenic non-human mammal.
14 . (canceled)
15 . The method of claim 8 , wherein the method comprises decreasing the chance of HIV infection in a subject that receives breast milk, the method comprising administering to breast milk: a composition comprising IgA antibody; a composition comprising multimeric antibody; or a composition comprising highly glycosylated antibody, to decrease the chance of HIV infection in a subject that receives the breast milk.
16 .- 19 . (canceled)
20 . The method of claim 15 , wherein the milk-produced IgA antibody is produced in the mammary gland of a transgenic non-human mammal.
21 . (canceled)
22 . The method of claim 8 , wherein the method comprises suppressing mother-to-child transmission of HIV.
23 . The method of claim 22 , wherein the method comprises applying: a composition comprising IgA antibody; a composition comprising multimeric antibody; or a composition comprising highly glycosylated antibody to the nipple of the mother prior to breast feeding to suppress mother-to-child transmission of HIV.
24 . (canceled)
25 . The method of claim 8 , wherein the method comprises suppressing mother-to-child transmission of HIV by expressing IgA antibody in one or more cells of the mammary gland of the mother to suppress mother-to-child transmission of HIV.
26 . (canceled)
27 . The method of claim 22 , wherein the mother is not a wet nurse.
28 . (canceled)
29 . (canceled)
30 . The method of claim 22 , wherein the IgA antibody is produced in the mammary gland of a transgenic non-human mammal.
31 .- 39 . (canceled)
40 . The method of claim 1 , wherein the administration or application results in the suppression of HIV replication in a target cell population
41 . The method of claim 1 , wherein the composition is capable of inducing antibody-dependent cell-mediated viral inhibition (ADC VI).
42 . The method of claim 1 , further comprising administering anti-retroviral therapy
43 . A composition comprising milk-produced IgA antibody.
44 . The composition of claim 43 , wherein the milk-produced IgA antibody is produced in the mammary gland of a transgenic non-human mammal.
45 . (canceled)
46 . (canceled)
47 . The composition of claim 43 , wherein the composition further comprises a pharmaceutically acceptable carrier.
48 . The composition of claim 43 , wherein the IgA antibody is an IgA1 antibody.
49 . The composition of claim 43 , wherein the IgA antibody is a dimeric IgA1 antibody.
50 . The composition of claim 43 , wherein the IgA antibody is an IgA2 antibody.
51 .- 62 . (canceled)